Plants with Hypolipidaemic Effects from Nigerian Flora by Nwodo, Ngozi Justina et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 10
Plants with Hypolipidaemic Effects from Nigerian Flora
Ngozi Justina  Nwodo, Charles Okeke Nnadi,
Akachukwu Ibezim and Chika John Mbah
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57181
1. Introduction
Definition: Hyperlipidemia is a heterogeneous group of disorders characterized by high level
of lipids (fats) in the bloodstream. These lipids include cholesterol, cholesterol esters, phos‐
pholipids, and triglycerides. Lipids are transported in the blood as large 'lipoproteins'.
Alternatively, the disease refers to elevated levels of lipids and cholesterol in the blood, or the
manifestations of different disorders of lipoprotein metabolism (dyslipidemia).
Causes: Hyperlipidemia could be caused by: (i) Familial combined hypercholesterolemia (ii)
Familial hypertriglyceridemia (iii) other disease states such as insulin and non-insulin dependent
diabetes mellitus, hypothyroidism, Cushing's syndrome, dysproteinemias, nephrotic syndrome and
renal failure, cholestatic disorders and low thyroid (iv) drugs such as anabolic steroids, beta-
blockers, birth control pills and estrogens, corticosteroids, protease inhibitors, retinoids,
thiazide diuretics (v) diets like cholesterol intake greater than 300 mg per day, fat intake per
total calories greater than 40 %, saturated fat intake per total calories greater than 10 % (vi) life
style involving habitual excessive alcohol use, lack of exercise, smoking (vii) risk factors such
as advancing age, sex (male), stress and postmenopause.
Classification: Lipoproteins are divided into five major classes, based on density and they
include: (i) chylomicrons (ii) very low-density lipoproteins (VLDL) (iii) intermediate-density
lipoproteins (IDL) (iv) low-density lipoproteins (LDL) and (v) high-density lipoproteins
(HDL). Most triglyceride is transported in chylomicrons or VLDL, while most cholesterol is
carried in LDL and HDL. Hyperlipidemia, a major, modifiable risk factor for atherosclerosis
and cardiovascular disease, including coronary heart disease (CHD) is classified under (1)
Primary hyperlipidemias - are probably genetically based, but the genetic defects are known
for only a minority of patients. Examples are (i) primary chylomicronemia- recessive traits of
deficiency of lipoprotein lipase or its cofactor (ii) familial hypercholesterolemia- an autosomal
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dominant trait, although levels of LDL tend to increase with normal VLDL; familial combined
(mixed) hyperlipoproteinemia- elevated levels of VLDL, LDL (iii) familial dysbetalipoprotei‐
nemia-increased LDL with increased TG and cholesterol levels (iv) familial hypertriglyceri‐
demia-increased VLDL production with normal or decreased LDL (v) familial mixed
hypertriglyceridemia-serum VLDL and chylomicrons are increased. (2) Secondary hyperlipi‐
demia- results from disease states such as Cushing's syndrome, diabetes, liver disorders, renal
disorders, thyroid disease, obesity, as well as alcohol consumption, estrogen administration,
and other drug-associated changes in lipid metabolism.
Symptoms: Hyperlipidemia usually does not cause symptoms. Very high levels of lipids or
triglycerides can cause yellowish nodules of fat in the skin beneath eyes, elbows and knees,
and in tendons (xanthomas). Sometimes pain, swelling of organs such as the liver, spleen or
pancreas (pancreatitis) or whitish rings around the eye's iris occur. Diagnosis: Diagnosis is
typically based on medical history, physical examination and most importantly blood test done
after overnight fasting. The blood test, measure the levels of lipids in the blood and consist of,
a fasting blood test for total cholesterol (TC), LDL (bad cholesterol), HDL (good cholesterol),
triglycerides (TG). American Cholesterol Education Program advises that lipids be checked at
least once every five years, starting at age 20. However, more frequent or earlier testing is
recommended if family history of hyperlipidemia; risk factor or disease that may cause
hyperlipidemia; complication that may result from hyperlipidemia exist. Also, the American
Academy of Pediatrics recommends lipid screening for children at risk (example, a family
history of hyperlipidemia and/or diabetes). Table 1 provides specifications for making a
determination.
Cholesterol level Acceptable Borderline High
Total Cholesterol (mg/dl) <170 170 – 199 ≥ 200
LDL Cholesterol (mg/dl) <110 110 – 129 ≥ 130
HDL Cholesterol (mg/dl) <40 40-59 ≥ 60
Total glycerides (mg/dl) <150 150-200 ≥ 200
Table 1. Classification of cholesterol level
Prevalence: (i) A significant percentage of world population has an increased plasma lipid
level, resulting in increased risk of coronary heart disease (ii) Ethnic groups adopting a
'western' lifestyle tend to have higher levels of plasma lipids (iii) Men >30 years and women
>55 years (in the U.S.) have10 % rise in fasting triglyceride level >200 mg/dl (iv) Severe
hypertriglyceridemia (>2000 mg/dl) higher in diabetic patients or patients suffering alcoholism
(iv) Lipoprotein lipase deficiency prevalence is much higher in Quebec, Canada. (v) total C
and LDL-C rise steadily about 20% in men aged 20 to 50 years, 30% in women aged 20 to 60
years and younger women have lower levels than men while homozygous familial hypercho‐
lesterolemia manifests itself from birth (vii) hyperlipidermia is higher among men than women
(gender factor) (viii) total cholesterol and LDL-C levels are similar in whites and blacks,
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triglycerides are lower and HDL-C levels tend to be higher in the African-American popula‐
tion. Asian-Indians have the highest risk, Europeans have an intermediate risk while Chinese
have the lowest risk (race factor) (ix) familial combined hyperlipidemia inheritance is autoso‐
mal dominant and likely to involve one of multiple enetic defects, familial hypertriglyceride‐
mia is most likely inherited as an autosomal dominant defect, lipoprotein lipase deficiency
and hepatic lipase deficiency are very rare autosomal recessive conditions hypercholesterole‐
mia in the majority of the general public is attributed to high-fat diets and poorly understood
susceptibility and modifier genes (genetics factor). Published data on the prevalence of lipid
abnormalities in Nigeria are scanty. This could be attributed to low prevalence of hyperlipi‐
demia in Nigeria prior to occidental lifestyle. Osuji et al, 2012, reported that the current state
of dyslipidemia in Nigeria clearly contradicts the previous perceptions. In their report,
dsylipidemia was found to be highly prevalent in Nigeria with consistent low HDL-cholesterol
and high LDL-c especially amongst the upper social class and people with other risk factors.
Other studies reported low HDL-c, with TC/HDL-c to be prevalent in the Northern part of the
country while high prevalence of TC, TG and low HDL were observed in the Southern part of
the country amongst people of upper social class.
2. Treatment
Dietary intervention: is the primary treatment strategy, but drug therapy may often be added
later to augment treatment. The main component of a “heart-healthy” diet is a food pattern
that is low in saturated fat and dietary cholesterol and provides adequate energy to support
growth and maintain an appropriate weight. Specific dietary recommendations include: (i)
decreased intakes of saturated fat- most effective in lowering LDL. Sources include stick
margarine, partially hydrogenated oils and fats, hydrogenated peanut butters, commercial
bakery products, commercial fried food (e.g., French fries) and high fat animal products (ii)
decreased intakes of trans-fatty acids- trans-fatty acids are thought to increase LDL levels
nearly as much as saturated fat and appear to lower HDL. (iii) decreased intakes of dietary
cholesterol- lead to LDL reduction. Diabetic patients tend to be more sensitive to dietary
cholesterol intake, which is only found in animal products (iv) balance the fatty acid compo‐
sition of diet- polyunsaturated and monounsaturated fatty acids can lower LDL and could be
good substitutes for saturated fats (v) increased fiber intakes- soluble fiber can contribute to
LDL reduction and is now a formal part of hyperlipidemia dietary recommendations. Com‐
mon sources of fiber include oats, psyllium, guar gum, pectin, barley, dried beans, fruits,
vegetables, cereals, whole grains, and legumes are good sources of soluble fiber (vi) encourage
antioxidant food sources such as carotenoids, vitamins C and E and antioxidant-rich foods
such as whole grains, citrus fruits, melons, berries and leafy green vegetables rather than
supplements (vii) reduce serum homocysteine levels- adequate intakes of folate and vitamins
B6 and B12 as well as total fat restriction may keep homocysteine levels low. Food sources of
these nutrients include fruits, dark green and leafy vegetables, fortified cereals, whole grains,
lean meats and poultry.
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Drug Therapy: Currently, there are many classes of medications that may be utilized in the
pharmacologic management of hyperlipidemia. They are (1) HMG-CoA (3-hydroxy-3-
methylglutaryl-coenzyme A) reductase inhibitors (statins). The cornerstone of the lipid-
lowering therapy in adults has rested with the HMG CoA reductase inhibitors or statins. The
use of these drugs has resulted in important reductions in overall cardiovascular morbidity
and mortality. Mechanism of action- reduction of cholesterol synthesis in liver; inhibiting the
rate-limiting step in endogenous cholesterol synthesis; compensatory increase in synthesis of
LDL receptors on hepatic and extra hepatic tissues; increase in hepatic uptake of circulating
LDL which decreases plasma LDL cholesterol; increase in HDL, decrease in TGs and vasodi‐
latation and decrease in atherosclerosis. Pharmacological indication: Clinically used in the
treatment of all types of hyperlipidemia except those who are homozygous for familial
hypercholesterolemia (lack of LDL receptors). Table 2 summarizes the statins and their
clinically applications.
Drug Starting Dose(mg)
FDA-Approved
Maximum (mg)
Half-life
(hours)
Average Decrease in
LDL-C Per Dose (mg:%)
Atorvastatin (lipitor) 10-20 80 14 or 20-30 10:39
20:43
80:60
Fluvastatin (Lescol) 20 80 3 20:22
80:35
Lovastatin (Mevacor) 20 80 2 20:28
Pitavastatin (Livalo) 2 4 12 2:36
4:43
Pravastatin (Pravachol) 40 80 2 40:34
80:37
Rosuvastatin (Crestor) 5-10 40 19 5:45
10:52
40:63
Simvastatin (Zocor) 20 80 4 20:38
80:36-47
Simvastatin/Ezetimibe (Vytorin) 10/10 10/40 22 10/10:45
10/40:55
Table 2. HMG-CoA INHIBITORS
(2) Fibrates (activators of lipoprotein lipase): Mechanism of action- agonists at peroxisome
proliferator-activated receptor (PPAR); hydrolysis of VLDL and chylomicrons; decrease in
serum TGs; increase clearance of LDL by liver and increase in HDL and expression of genes
responsible for increased activity of plasma lipoprotein lipase enzyme. Pharmacological
indication: most effective in reduction TGs (hypertriglyceridemia); combined hyperlipidemia
(type III) if statins are contraindicated. Typical examples are fenofibrate(prodrug) and
gemfibrozil (lopid) (3) Ezetimibe: Mechanism of action- inhibits intestinal cholesterol and
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related phytosterol absorption; decrease in concentration of intrahepatic cholesterol; increase
in uptake of circulating LDL; decrease in serum LDL cholesterol levels and compensatory
increase in LDL receptors. Pharmacological indication: Effective in hypercholesterolemia
together with statins and diet regulation; utilization of ezetimibe along with a statin allows for
lower doses of the statin to be used, therefore reducing the likelihood of dose-related side
effects of the statin. (4) Nicotinic acid; Niacin (Inhibitor of lipolysis): Mechanism of action- a
potent inhibitor of lipolysis in adipose tissues; decreases mobilization of FFAs (major precursor
of TGs) to the liver; increases HDL levels; decreases LDL, decreases endothelial dysfunction
and thrombosis. Pharmacological indication- Used in the treatment of familial hyperlipide‐
mias (type IIB) (increase in VLDL and LDL); combined with fibrates or cholestyramine in the
treatment of hypercholesterolemia (5) Bile acids- Sequestrants(resins): The bile acid binding
resins have been felt to be preferred in the pediatric age group as they are not systemically
absorbed. Mechanism of action- are anion exchange resins; bind bile acids in the intestine
forming complex that leads to loss of bile acids in the stools; increase the conversion of
cholesterol into bile acids in the liver; compensatory increase in LDL receptors leading to
decreased concentration of intrahepatic cholesterol; increase hepatic uptake of circulating LDL
and decrease serum LDL cholesterol levels. Pharmacological indication: Effective in the
treatment of type IIA and IIB hyperlipidemias (along with statins when response to statins is
inadequate or they are contraindicated); treatment of pruritus in biliary obstruction (as rising
from increase in bile acids). Typical examples are cholestyramine, colestipol and colesevelam.
(6) Lovaza (Omega-3-acid ethyl ester): Mechanism of action: is unclear; however, proposed
mechanisms include decreasing lipogenesis in the liver, increasing plasma lipoprotein lipase
activity, and increasing mitochondrial and perixosomal lipase activity. The drug may increase
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and has also been
known to prolong bleeding time. Pharmacological indication: is indicated as adjunct therapy
to diet in patients with triglyceride levels greater than or equal to 500 mg/dl (hypertriglyceri‐
demia). It provides significant reduction in triglycerides, of approximately 44.9%, making it
an ideal drug choice in patients with high triglycerides (7) Fish oil is another common over-
the-counter (OTC) product that provides an alternative to the prescription product Lovaza (8)
OTC herbal product: (i) Red yeast rice (RYR)- herbal supplements used for lipid-lowering
effects. RYR is obtained by fermenting Monascus purpureus, a form of yeast, on rice, which is
then dried, pulverized, and encapsulated. This process leads to the formation of 14 monacolins,
which are compounds that inhibit HMG-CoA reductase. One of the mona-colins, monacolin
K (lovastatin or mev-inolin) was the first synthesized HMG-CoA reductase inhibitor. RYR is
commercially available in 600-mg capsules (ii) Plant sterols and stanols also assist in the
reduction of LDL-C. Plant sterols reduce cholesterol absorption by competing with cholesterol
for space within bile salt micelles in the intestinal lumen. The plant stanols, which are the result
of the hydrogenation of sterols, are not absorbed as well as sterols. Ingestion of about 2 g per
day of plant sterols or stanols, produces LDL-C reduction of 6% to 15%. Prevention: Cardio‐
vascular disease (CVD) is the leading cause of mortality in advance countries, with hyperli‐
pidemia a common risk factor for CVD, in adults having abnormal cholesterol values and
elevated low-density lipoprotein (LDL) cholesterol levels. Prevention could be subdivided
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into: Primary prevention- (i) initial treatment is diet/exercise and should be given three to six
months on dietary therapy prior to beginning medication and longer if lipids are improving
and nearing LDL thresholds (ii) obtain cholesterol tests starting at the age of 20 (iii) eat a diet
low in total fat, saturated fat, and cholesterol namely eat poultry without the skin, fish,
vegetables, most fruits, whole grains, and skim milk (iv) reduce sugar intake (v) eat foods high
in soluble fiber (vi) eat more cold water fish and soy products (vii) avoid cigarette smoking
(viii) drink alcohol in moderation (two drinks per day for men, one drink per day for women)
(ix) avoid overweight (x) exercise regularly and control blood sugar if diabetes is implicated
(xi) increase physical activity (xii) consume a diet that contains adequate potassium, calcium,
and magnesium to facilitate blood pressure control. Secondary prevention: Measuring lipids
in adolescents that have strong family history of two or more coronary heart disease risk
factors. In summary, US National Cholesterol Education Program (NCEP) Adult Treatment
Panel III (ATP III in its guidelines has communicated the importance of early identification of
risk, lifestyle modification, and pharmacologic treatment as the mainstay of therapy for
hyperlipidemia and in the prevention of cardiovascular-related death.
The Promise of Nigeria Natural Products: Since the recognition of hyperlipiermia, a large
number of plant species have been identified as having antihyperlipidermic properties and
natural products are part of the current therapy for hyperlipidermia. Numerous natural
products with antihyperlipidemic effect have been described in the literature. The objective of
this chapter is to summarize the role of Nigeria natural products in the treatment and preven‐
tion of hyperlipidermia to date and to highlight specific classes of compounds that possess a
requisite level of activity that would be considered worthy of further investigation as potential
drug candidate.
3. Discussion
3.1. Antilipidemic agents from Nigeria flora
In Nigeria, traditional medicine has been the most popular means of healthcare from the olden
days, before the emergence of alternative medicine in the form of synthetic agents. Traditional
medicine can be said to be indigenous and a culture handed over to us by our anscestors as a
means of surviving from various ailment obvious in every society. Due to high cost of synthetic
drugs and side effects, natural products have become the best alternative strategy for the
development of safe antilipidemic drugs. Various natural products both crude and isolated
components found from plants are effective remedies for hyperlipidemia cases. Several proves
are available in nature, indicating the positive effects of many natural product components
that can be employed for the treatment of hyperlipidemia. Ibrahim et al, 2013 stated that
polyphenols as apigenin, genistein and catechins as well as saponins, sterols, stanols polyun‐
saturated fatty acids, mucilage and carbohydrates are good examples of agents found to exhibit
potent hypocholesterolemic activities. Table3 summarizes the continuous investigations of
Nigerian plants used as antihyperlipidemia from ethnopharmacological approach based on
the folkloric claims.
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Sources Morphological parts Comments References
PerseaAmerican (Avocado
pea)
Leaves, methanolic extract Hypolipidemic activity at 40
mg/kg
Kolawole et al., 2012
Garciniakola Root and seed, normal saline
extracts
Hypolipidemic activity at
300-900 mg/kg
Udenze et al., 2012
Viscumalbum Plant parts, methanolic
extract
Hypolipidemic activity at
50-100 mg/kg
Oluwatosin et al., 2012
Caricapapaya Seed, aqueous extract Hypolipidemic activity at
100-400 mg/kg
Nwangwa and Ekhoye 2013
Emilapraetermissa Leaves, aqueous extract Hypolipidemic activity Anaka et al., 2013
Cleistopholis patens Leaves, aqueous extract Hypolipidemic activity at
400-600 mg/kg
Udem et al., 2011
Solanumanguivi,
S. macrocarpum
Fruit, aqueous extract Hypolipidemic activity at
20-100 mg/kg
Elekofehiniti et al. 2012;
Sodipo et al., 2011
Annonamuricata Plant parts, methanolic
extract
Hypolipidemic activity Adeyemi et al., 2009
Nauclealatifolia Root and stem bark, ethanolic
extract
Hypolipidemic activity at
100-150 mg/kg
Odey et al., 2013
Acalypha torta
A. capitata
Leaves, aqueous extract Hypolipidemic activity at
100-200 mg/kg
Nnodim et al, 2011
Scopariadulcis Plant (herb) parts, methanolic
extract
Hypolipidemic activity Orhue and Nwanze, 2006
Alchorneacordifolia Leaves, butanolic extract Hypolipidemic activity at 800
mg/kg
Mohammed et al., 2012
Vernonia amygdalina
Vernonia amygdalina
Plant parts, methanolic
extract; Leaves, ethanolic
extract; root, normal saline
extract
Hypolipidemic activity
Hypolipidemic activity at
100-200 mg/kg
Oluwatosin et al., 2008
Igbakin 2009, Owen et al.,
2011
Moringa oleifera Leaves, aqueous extract Hypolipidemic activity at 1
mg/g
Ghasi et al., 2000
Clerodendrumcapitalum Leaves, aqueous extract Hypolipidemic activity at
100-800 mg/kg
Adenaya et al., 2008
Parkiabiglobosa Plant parts, methanolic
extract
Hypolipidemic activity at
30-60 mg/kg
Odetola et al., 2006
Citrusparadisi Seed, methanolic extract Hypolipidemic activity at
100-600 mg/kg
Adeneye, 2008
Cymbopogoncitrates Leaves, aqueous extract Hypolipidemic activity at
125-500 mg/kg
Adeneye & Agbaje, 2007
Catharanthusroseus Leaves, aqueous extract Hypolipidemic activity at1
ml/kg
Antia & Okokon, 2005
Albizziachevalieri Root, aqueous extract Hypolipidemic activity at
100-300 mg/kg
Saidu et al., 2010
Stachytarphelaaugustifolia Aerial part, methanolic extractHypolipidemic activity Garba et al., 2013
Vitexdoniana Leaves, ethanolic extract Hypolipidemic activity Oche et al., 2012
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Sources Morphological parts Comments References
Morindamorindoides Root bark, methanolic extract Hypolipidemic activity Olukunle et al., 2012
Arachishypogaea Plant parts, aqueous extract Hypolipidemic activity at 175
mg/kg
Bilbis et al., 2002
“Ata-Ofa’ (polyherbal tea) Leaves, methanolic extract Hypolipidemic activity at 50
mg/kg
Atawodi, 2001
Xylopiaaethiopica Seed, methanolic extract Hypolipidemic activity at 250
mg/kg
Nwozo et al., 2011
Parinaripolyandra Fruit, ethanolic extract Hypolipidemic activity at
50-250 mg/kg
Abolaji et al., 2007
Telfairia occidentalis Plant parts,
methanolic extract
Hypolipidemic activity Adaramoye et al., 2007
Curcuma longa methanol extract of the
rhizomes
hypoglycemic and
hypolipidemic acitivity 100
mg/kg
Nwozo et al, 2009.
Spondiamombia Aqueous leave extract Lipid lowering effect at the
doses of 250, 500and 750
mg/kg
Igwe et al, 2008
Crotonzambesicus Ethanolic leaf extract Lipid lowering effect Ofusori et al, 2012.
Momordicacharantia Linn Methanolic extract of the
fruits
Anti-Diabetic and
Hypolipidemic Effects at the
doses of 200, 400 and 600
mg/kg
Kolawole and Ayankunle,
2012.
Bauhiniathoningii Aqueous crude extract Hypoglycemic and lipidemic
effecte
Ojezele and Abatan, 2011.
Cajanuscajan Methanolic leaf extract Antioxidant and
hypolipidemic activity at the
dose of 200 mg/kg
Akinloye and Solanke 2011.
Jatrophatanjorensis Methanolic leaf extract Serum lipid profile and
phytochemical composition at
100, 200 and 500mg/kg dose
ranges
Oluwole et al, 2011.
Melantherascandens Ethanolic leaf extract Antidiabetic and
hypolipidemic activities at the
doses of 37, 74 &111 mg/kg
Akpan et al, 2012.
Ricinuscommunis Aqueous root extract Hypoglycaemic potential, lipid
profile effects At a dose of
500mg/kg
Matthew et al, 2012.
Table 3. Medicinal plants investigated in Nigeria for use as Antihypolipidemic agent
These plants have been identified, authenticated and investigated from Nigeria flora against
hyperlipidemia, using pharmacological validated animal models. They all have levels and
with some levels of increase in LDL, TC, TG and decrease in HDL. Furthermore, there has been
recent interest on the research towards hyperlipidemia due to its obvious relationship with
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diabetes and other ailments like cushing’s syndrome, renal disorder, pregnancy, polycystic
ovary syndrome, underactive thyroid gland etc. Hyperlipidemia arising from high serum
triglyceride or total cholesterol concentration or both has been reported in diabetic and
hypertensive patients. Diabetics have been reported to be more prone to cardiovascular
diseases including hypertension than non-diabetics (Bilbis et al, 2002). An overview of 40
medicinal plant species from Nigerian indigenous plants reported to have hypolipidemic
effects are presented. Most of the reported hypolipidemic effects were on crude extracts and
active constituents. Above 30 % of the investigated plant parts had effects on both lipid profile
and glyceamic index. However, much still needs to be done on several phytoconstituents of
these plants, as well as conduct clinical research on active constituents derived from them,
especially in the determination of their levels of toxicity. Other Nigerian plants claimed to have
positive effects on lipid profile but found to act as soup thickeners are yet to be investigated.
The reported Nigerian plants in Table 3 are rich in soluble and dietary fibres ( examples,
legumes, fruits and vegetables) and if found to have minimal toxicities, can be incorporated
into dietary supplements. According to Ibrahim et al, (2013), the major advantage of natural
hypolipidemic drugs over synthetic drugs is that many natural drugs exhibit their hypolipi‐
demic activity by different mechanisms. Plants are known to have a striking potential in the
management of lipid metabolism and providing better therapeutic effects as an alternative
medicine.
4. Conclusion
The use of herbal or natural medicines for the treatment of various disorders has a long and
extensive history. The reported plants have the potential to act as lipid-lowering agents with
minimal side effects (advantage over currently synthetic drugs) and thus could find their way
onto the world market as alternatives to prescribed drugs currently available to treat hyper‐
lipidermia. Most of the studies were carried out with crude extract and administered orally.
The principal families in which such activity has been reported are Acanthaceae, Apiaceae,
Asteraceae, Azoaceae, Combretaceae, Cucurbitaceae, Euphorbiaceae, Fabaceae, Lamiaceae,
Liliaceae, Malvaceae, Myrtaceae, Rubiaceae, Rutaceae and Zingiberaceae, Finally, all the plant
species appear to be promising as hypolipidemic agents with activity mediated through
various mechanisms.
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